Anti-CTLA-4 at a low dose (33 μg per mouse) also improves survival in a two hit model of sepsis, comprised of slowly progressive CLP-induced sepsis followed by infection with a fungus, Candida albicans [48]. This evidence concerns the gene CTLA4 and Sepsis.